# Data Sheet (Cat.No.T0083)

TargetMol

## Eplerenone

### Chemical Properties



CAS No. : 107724-20-9

Formula: C24H30O6

Molecular Weight: 414.49

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

### Biological Description

| | |
|---|---|
| Description | Eplerenone (CGP 30083) is an aldosterone receptor antagonist and potassium-sparing diuretic used in the therapy of hypertension. Eplerenone therapy has been associated with transient elevations in serum aminotransferase levels, but has yet to be linked to cases of clinically apparent drug induced liver disease. |
| Targets(IC50) | Glucocorticoid Receptor |
| In vitro | Eplerenone increases total vascular and luminal areas in swine without affecting the endothelial area. In canine models, it significantly reduces left ventricular end-diastolic wall stress. Eplerenone attenuates the rise in pulse pressure due to aldosterone (Aldo) in rats, normalizing the wall stress curve, mean cross-sectional area, and EIIIA fibronectin levels in Aldo-salt hypertensive rats. The compound upregulates diminished endothelial nitric oxide synthase mRNA in Dahl salt-sensitive hypertensive (DS) rats, markedly improving glomerulosclerosis and proteinuria. In mice, daily administration of 200 mg/kg of Eplerenone significantly lowers systolic and diastolic blood pressures compared to controls and increases serum phosphatase activity. |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 4.1 mg/mL (9.89 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 2.4126 mL | 12.063 mL | 24.126 mL |
| 5 mM | 0.4825 mL | 2.4126 mL | 4.8252 mL |
| 10 mM | 0.2413 mL | 1.2063 mL | 2.4126 mL |
| 50 mM | 0.0483 mL | 0.2413 mL | 0.4825 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Kobayashi N, et al. Hypertension, 2005, 45(4), 538-544.
Keidar S, et al. J Cardiovasc Pharmacol, 2003, 41(6), 955-963.
Ward MR, et al. Circulation, 2001, 104(4), 467-472.
Suzuki G, et al. Circulation, 2002, 106(23), 2967-2972.
Lacolley P, et al. Circulation, 2002, 106(22), 2848-2853.



Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481